Year :
2023
| Month :
August
| Volume :
17
| Issue :
8
| Page :
DD01 - DD03
Full Version
Cupriavidus gilardii Pneumonia in a Young Patient with Chronic Kidney Disease: A Case Report
Published: August 1, 2023 | DOI: https://doi.org/10.7860/JCDR/2023/63547.18403
Ashima Jamwal, Mitra Kar, Akanksha Dubey, Nidhi Tejan, Chinmoy Sahu
1. Senior Resident, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
2. Senior Resident, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
3. Senior Resident, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
4. Assistant Professor, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
5. Additional Professor, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Correspondence Address :
Dr. Chinmoy Sahu,
Additional Professor, Department of Microbiology, C-Block, 2nd Floor, SGPGIMS, Lucknow-226014, Uttar Pradesh, India.
E-mail: csahu78@rediffmail.com
Abstract
Cupriavidus gilardii (C. gilardii) is a Gram-negative, motile, non sporulating, non lactose fermenting bacterium. It was first identified by Coenye et al., and has a complex taxonomy, often being misidentified as Wausteria gilardii, Ralstonia gilardii. It is commonly found in ecosystems containing plants and heavy metal-contaminated soil and is rarely isolated from clinical samples with no clear evidence of its clinical significance. The pathogenic nature of C. gilardii in respiratory ailments, particularly in patients with cystic fibrosis, is still unclear. This case report presents a 19-year-old female with Chronic Kidney Disease (CKD) who developed pneumonia caused by C. gilardii. The report also includes the sensitivity pattern of the bacterium to guide physicians in treating these rare pathogens.
Keywords
Cystic fibrosis, Ecosystems, Ralstonia gilardii, Soil
Case Report
A 19-year-old female, a known case of CKD with bilateral small kidneys, presented to the emergency outpatient department with chief complaints of progressively worsening cough with expectoration and occasional episodes of blood in vomit for the past one week, followed by low-grade fever for the past five days. She had been in contact with a positive case of tuberculosis within the family and was suspected to have pulmonary tuberculosis at a Community Healthcare Centre (CHC). She was administered oral tablet levofloxacin 400 mg BD for two weeks, but no improvement in her symptoms was observed. She was then referred to a tertiary care centre.
On examination, a consulting physician observed a pulse rate of 156 beats per minute and a blood pressure of 137/70 mmHg, with a respiratory rate of 28 breaths per minute. The partial pressure of oxygen was recorded as 89% on ambient air. A High Resolution Computed Tomography (HRCT) of the chest was performed, which revealed nodular lesions in both lungs (Table/Fig 1).
All routine tests were performed on admission, and the results are represented in (Table/Fig 2). The patient was admitted, and her procalcitonin assay was elevated (29.49 ng/mL), suggestive of an underlying infectious aetiology. A deeply expectorated sputum sample was sent to the bacteriology section of the Department of Microbiology. A Gram-stained smear and Ziehl-Neelsen (ZN) stain were prepared from the sample. On microscopy, the Gram-stained smear observed at 100X magnification showed a few epithelial cells, a few pus cells, and plenty of gram-negative bacilli (Table/Fig 3).
No acid-fast bacilli were observed on the ZN-stained smear. The sample was inoculated on MacConkey’s and Blood agar and incubated overnight in an aerobic incubator at 37ºC. After 16-18 hours of incubation, late-lactose fermenting colonies were observed on MacConkey agar (Table/Fig 4).
Chocolate agar was not used in this laboratory. The identification of the bacteria was confirmed by Matrix-Assisted Laser Desorption/Ionisation-Time of Flight-Mass Spectrometry (MALDI-TOF-MS) with a confidence percentage of 99%. To confirm the isolation of this microorganism from respiratory secretions, a repeat sample was advised, and growth of the same microorganism was observed. Antibiotic sensitivity testing was performed using the Kirby Bauer disc diffusion method on cation-adjusted Muller-Hinton Agar (MHA) and interpreted according to CLSI guidelines 2023 (1). The isolate was found to be susceptible to ceftazidime, chloramphenicol, trimethoprim-sulfamethoxazole, and levofloxacin (Table/Fig 5).
The patient was started on ceftriaxone empirically before the antibiotic sensitivity report was acknowledged, and thereafter, she was managed with trimethoprim-sulfamethoxazole 80 mg/400 mg BD for five days. After three days of treatment, she was relieved of fever and expectoration. Due to financial constraints, she was unable to afford further treatment but returned to the pulmonary outpatient department with all organ systems, especially the respiratory system, within normal physiological limits.
Discussion
C. gilardii is a Gram-negative, motile, non sporulating, non lactose fermenting bacterium (2). It was first identified by Coenye T et al., and has a complex taxonomy. It has been misidentified as Wausteria gilardii, Ralstonia gilardii (3),(4). It is commonly found in the environment, specifically in plants and heavy metal-contaminated soil. It is rarely isolated from clinical samples, and its clinical significance is not well-established (2),(5),(6). The pathogenic nature of C. gilardii in respiratory ailments, particularly in patients with cystic fibrosis, is still not clear (5).
Due to its rarity in clinical isolates, there is limited literature available on infections caused by C. gilardii. This case report presents a review of all reported cases of C. gilardii infection in humans (Table/Fig 6) (7),(8),(9),(10),(11). Previous cases of infection with C. gilardii involved immunocompromised patients with underlying conditions such as renal transplant (7), acute lymphocytic leukaemia (8), idiopathic aplastic anaemia (9), patients with pacemaker support (10), and Chronic Obstructive Pulmonary Disease (COPD) (11). Advancements in diagnostic modalities like MALDI-TOF-MS have improved the accuracy of identifying C. gilardii from clinical samples compared to earlier cases where biochemical tests played a significant role (10).
In the literature, all studies have identified C. gilardii as an opportunistic pathogen causing infections in immunocompromised patients. In this case, the patient was immunocompromised due to CKD with elevated urea levels and sepsis, indicated by high procalcitonin levels. The age of the patient in this case aligns with the age range of previously reported cases (36, 7, and 12 years old) (7),(8),(9). The patient had no history of contact with soil and plants, so the source of the pathogen could not be identified.
C. gilardii is intrinsically resistant to a spectrum of antibiotics (10). This case report mentions that the microorganism showed susceptibility to trimethoprim-sulfamethoxazole, consistent with previous reports (7),(8),(9). The isolate in this case was also found to be susceptible to levofloxacin in-vitro, but it was not used due to the microorganism’s ability to easily develop resistance, limiting the effectiveness of most drugs (9),(10).
Conclusion
This case report describes the sixth reported case of infection caused by C. gilardii. Although the source of infection could not be identified in this case report, the isolation of the microorganism from two consecutive sputum samples and the clinical symptoms of the patient were indicative of its pathogenic nature. A larger study cohort is needed to further investigate the characteristics and pathogenicity of C. gilardii.
Reference
| 1. | Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Thirty-third informational supplement. Clinical and Laboratory Standards Institute. CLSI document M100Ed33. Wayne, PA, USA (2023).
| 2. | Cuadrado V, Gomila M, Merini L, Giulietti AM, Moore ER. Cupriavidus pampae sp. nov., a novel herbicide-degrading bacterium isolated from agricultural soil. Int J Syst Evol Microbiol. 2010;60(11):2606-12.
[ CrossRef] [ PubMed] | 3. | Coenye T, Falsen E, Vancanneyt M, Hoste B, Govan JR, Kersters K, et al. Classification of Alcaligenes faecalis-like isolates from the environment and human clinical samples as Ralstonia gilardii sp. nov. Int J Syst Bacteriol. 1999;49(2):405-13.
[ CrossRef] [ PubMed] | 4. | Vandamme P, Coenye T. Taxonomy of the genus Cupriavidus: A tale of lost and found. Int J Syst Evol Microbiol. 2004;54(6):2285-89.
[ CrossRef] [ PubMed] | 5. | Coenye T, Vandamme P, LiPuma JJ. Infection by Ralstonia species in cystic fibrosis patients: Identification of R. pickettii and R. mannitolilytica by polymerase chain reaction. Emer Infect Dis. 2002;8(7):692.
[ CrossRef] [ PubMed] | 6. | Vandamme P, Goris J, Coenye T, Hoste B, Janssens D, Kersters K, et al. Assignment of Centers for Disease Control group IVc-2 to the genus Ralstonia as Ralstonia paucula sp. nov. Int J Syst Bacteriol. 1999;49(2):663-69.
[ CrossRef] [ PubMed] | 7. | Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Muscular abscess caused by Cupriavidus gilardii in a renal transplant recipient. Diag Micribiol Infect Dis. 2014;79(1):108-10.
[ CrossRef] [ PubMed] | 8. | Wauters G, Claeys G, Verschraegen G, De Baere T, Vandecruys E, Van Simaey L, et al. Case of catheter sepsis with Ralstonia gilardii in a child with acute lymphoblastic leukaemia. J Clin Microbiol. 2001;39(12):4583-84.
[ CrossRef] [ PubMed] | 9. | Karafin M, Romagnoli M, Fink DL, Howard T, Rau R, Milstone AM, et al. Fatal infection caused by Cupriavidus gilardii in a child with aplastic anemia. J Clin Microbiol. 2010;48(3):1005-07.
[ CrossRef] [ PubMed] | 10. | Kobayashi T, Nakamura I, Fujita H, Tsukimori A, Sato A, Fukushima S, et al. First case report of infection due to Cupriavidus gilardii in a patient without immunodeficiency: A case report. BMC Infect Dis. 2016;16:01-04.
[ CrossRef] [ PubMed] | 11. | Zhang Z, Deng W, Wang S, Xu L, Yan L, Liao P. First case report of infection caused by Cupriavidus gilardii in a non-immunocompromised Chinese patient. IDCases. 2017;10:127-29. [ CrossRef] [ PubMed] |
DOI: 10.7860/JCDR/2023/63547.18403
Date of Submission: Feb 16, 2023
Date of Peer Review: May 12, 2023
Date of Acceptance: Jun 27, 2023
Date of Publishing: Aug 01, 2023
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. No
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Feb 18, 2023
• Manual Googling: May 30, 2023
• iThenticate Software: Jun 22, 2023 (7%)
ETYMOLOGY: Author Origin
EMENDATIONS: 6
|